RxDoctor Payments Data

Ronald Kristensen, MD

Orthopaedic Surgery · Boise, IDNPI 1215948807

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Stryker at 48.5% of the total. Reporting peaked in 2019 at $11,522 and has fallen 84.2% since, to $1,821 in 2025.

$28,808in general payments, 2019–2025

Across 440 payments — averaging $65.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$14K
  • Medical Device Business Services, Inc.$10K
  • Johnson & Johnson$2K
  • Heron Therapeutics, Inc.$806
  • Smith+Nephew$576
  • Zimmer Biomet$529
  • plus $817 from 9 others

What the payments were for

  • Consulting fees$8,77530%
  • Travel & lodging$7,02624%
  • Food & beverage$13,00745%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,808 in reported general payments places this provider in the 85th percentile of 139 orthopaedic surgery providers in Idaho.

See all orthopaedic surgery providers in Idaho

Medicare billing

Part B allowed, 2024
$249,466
Medicare patients
243
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$8,990
Hydroxyzine Hcl487$3,156
Tramadol Hcl536$2,485
Pregabalin212$1,857
Omeprazole219$1,745
Oxycodone Hcl278$899
Amoxicillin402$651
Cefadroxil79$578
Mupirocin56$379
Ondansetron Hcl42$261
Celecoxib18$254
Clindamycin Hcl78$220
Tamsulosin Hcl12$81
Hydromorphone Hcl14$46
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$45

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$8,99013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 139 orthopaedic surgery providers in Idaho.

Other orthopaedic surgery in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →